<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The effects of the <z:chebi fb="0" ids="35623">anticonvulsant</z:chebi> gabapentin were measured on vision and eve movements in three patients with acquired <z:hpo ids='HP_0012043'>pendular nystagmus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In two patients, the <z:hpo ids='HP_0000639'>nystagmus</z:hpo> was associated with multiple <z:mp ids='MP_0000612'>sclerosis</z:mp> and, in the other, it followed brainstem <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>A single oral 600 mg dose of gabapentin produced improvement of vision due to changes in ocular oscillations in <z:hpo ids='HP_0000001'>all</z:hpo> three patients </plain></SENT>
<SENT sid="3" pm="."><plain>The effect was sustained after five weeks of treatment in two patients who elected to continue taking gabapentin 900-1500 mg/day </plain></SENT>
<SENT sid="4" pm="."><plain>The results of this pilot study suggest that a controlled trial of gabapentin should be conducted to evaluate its role in the treatment of acquired forms of <z:hpo ids='HP_0000639'>nystagmus</z:hpo> </plain></SENT>
</text></document>